Denis Furling
Furling, Denis, 19..-....
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
VIAF ID: 296368740 (Personal)
Permalink: http://viaf.org/viaf/296368740
Preferred Forms
-
100 0 _
‡a
Denis Furling
-
100 1 _
‡a
Furling, Denis,
‡d
19..-....
4xx's: Alternate Name Forms (2)
Works
| Title | Sources |
|---|---|
| IL-13 mediates the recruitment of reserve cells for fusion during IGF-1-induced hypertrophy of human myotubes |
|
| The aberrant inclusion of BIN1 exon 7 in DM1 muscle contribute to the muscle weakness and atrophy of the patients. |
|
| Abnormal prostaglandin E2 production blocks myogenic differentiation in myotonic dystrophy |
|
| Abnormal splicing switch of DMD's penultimate exon compromises muscle fibre maintenance in myotonic dystrophy |
|
| Activation of the interferon type I response rather than autophagy contributes to myogenesis inhibition in congenital DM1 myoblasts |
|
| Altered signal transduction pathways and induction of autophagy in human myotonic dystrophy type 1 myoblasts |
|
| Analysis of exonic regions involved in nuclear localization, splicing activity, and dimerization of Muscleblind-like-1 isoforms |
|
| Association Between Mutation Size and Cardiac Involvement in Myotonic Dystrophy Type 1: An Analysis of the DM1-Heart Registry |
|
| CRISPR/Cas9-Induced (CTG⋅CAG)n Repeat Instability in the Myotonic Dystrophy Type 1 Locus: Implications for Therapeutic Genome Editing. |
|
| Decreased levels of myotonic dystrophy protein kinase (DMPK) and delayed differentiation in human myotonic dystrophy myoblasts |
|
| A defective Krab-domain zinc-finger transcription factor contributes to altered myogenesis in myotonic dystrophy type 1 |
|
| Defective mRNA in myotonic dystrophy accumulates at the periphery of nuclear splicing speckles |
|
| Développement de dérivés de MBNL pour la thérapie des dystrophies myotoniques. |
|
| Développement de vecteurs adéno-associés recombinants ciblant le muscle pour le transfert de gène et d'approches d'édition du génome pour la myopathie de Duchenne |
|
| Develpment of gene therapy for Myotonic Dystropy type 1. |
|
| Downregulation of the Glial GLT1 Glutamate Transporter and Purkinje Cell Dysfunction in a Mouse Model of Myotonic Dystrophy. |
|
| The dysregulation of miR-1 and its target multiplexin and their implication in heart defects associated with myotonic dystrophy type 1. |
|
| Dystrophin and central nervous system : Towards a treatment by exon skipping of cognitive defects in Duchenne muscular dystrophy. |
|
| Dystrophin restoration therapy improves both the reduced excitability and the force drop induced by lengthening contractions in dystrophic mdx skeletal muscle |
|
| Dystrophine et système nerveux central : vers un traitement par saut d'exon des défauts cognitifs de la myopathie de Duchenne |
|
| Effect of constitutive inactivation of the myostatin gene on the gain in muscle strength during postnatal growth in two murine models |
|
| Endogenous TWIST expression and differentiation are opposite during human muscle development |
|
| L’étude des conséquences du défaut d’épissage de serca1 sur la fonction musculaire dans la dystrophie myotonique de type 1. |
|
| Étude d'un transcrit alternatif de la dysferline et mise en place d'un traitement pour les dysferlinopathies |
|
| Etude par approches globales de la sélectivité d'atteinte dans les dystrophies des ceintures |
|
| Exon skipping as a therapeutic approach for Dystrophic Epidermolysis Bullosa. |
|
| Exon skipping therapy application to structural myopathy and Lowe syndrome. |
|
| Expansion de triplets CTG et arrêt prolifératif précoce des myoblastes DM1 |
|
| Expression of miR-1, miR-133a, miR-133b and miR-206 increases during development of human skeletal muscle. |
|
| Extended Amplification In Vitro and Replicative Senescence: Key Factors Implicated in the Success of Human Myoblast Transplantation |
|
| Gain of RNA function in pathological cases: Focus on myotonic dystrophy. |
|
| High-content screening identifies small molecules that remove nuclear foci, affect MBNL distribution and CELF1 protein levels via a PKC-independent pathway in myotonic dystrophy cell lines |
|
| High Risk of Fatal and Nonfatal Venous Thromboembolism in Myotonic Dystrophy |
|
| Human circulating AC133+ stem cells restore dystrophin expression and ameliorate function in dystrophic skeletal muscle |
|
| Immortalized human myotonic dystrophy muscle cell lines to assess therapeutic compounds. |
|
| Immunocytochemical localization of seleno-glutathione peroxidase in the adult mouse brain |
|
| Impact de l'inclusion du domaine C-terminal de la dystrophine sur l'efficacité d'une micro-dystrophine dans le cadre d'une thérapie génique de la Dystrophie Musculaire de Duchenne |
|
| Impairment of synaptic transmission by transient hypoxia in hippocampal slices: improved recovery in glutathione peroxidase transgenic mice |
|
| Improvement of Dystrophic Muscle Fragility by Short-Term Voluntary Exercise through Activation of Calcineurin Pathway in mdx Mice |
|
| In-depth analysis of the secretome identifies three major independent secretory pathways in differentiating human myoblasts |
|
| In Vitro and In Vivo Modulation of Alternative Splicing by the Biguanide Metformin |
|
| Large CTG repeats trigger p16-dependent premature senescence in myotonic dystrophy type 1 muscle precursor cells |
|
| Lentiviral vector-mediated overexpression of mutant ataxin-7 recapitulates SCA7 pathology and promotes accumulation of the FUS/TLS and MBNL1 RNA-binding proteins |
|
| L'IGF-1 induit une augmentation de la taille et du contenu en myosine des myotubes humains |
|
| Mechanical Overloading Increases Maximal Force and Reduces Fragility in Hind Limb Skeletal Muscle from Mdx Mouse |
|
| Misregulated alternative splicing of BIN1 is associated with T tubule alterations and muscle weakness in myotonic dystrophy. |
|
| Molecular, physiological, and motor performance defects in DMSXL mice carrying >1,000 CTG repeats from the human DM1 locus |
|
| Muscleblind-like proteins: similarities and differences in normal and myotonic dystrophy muscle |
|
| Myocytes from congenital myotonic dystrophy display abnormal Na+ channel activities |
|
| MyoD transcription factor induces myogenesis by inhibiting Twist-1 through miR-206 |
|
| Nesprins, but not sun proteins, switch isoforms at the nuclear envelope during muscle development. |
|
| New function for the RNA helicase p68/DDX5 as a modifier of MBNL1 activity on expanded CUG repeats |
|
| Nuclear protein spreading: implication for pathophysiology of neuromuscular diseases. |
|
| Perte des protéines MBNL dans les motoneurones : impact sur la fonction de l'unité motrice dans la Dystrophie myotonique |
|
| Pluripotent Stem Cell-Based Drug Screening Reveals Cardiac Glycosides as Modulators of Myotonic Dystrophy Type 1 |
|
| Potassium currents in human myogenic cells from healthy and congenital myotonic dystrophy foetuses |
|
| Precise small-molecule recognition of a toxic CUG RNA repeat expansion. |
|
| Preclinical development of tcDNA for Duchenne Muscular Dystrophy. |
|
| Progressive skeletal muscle weakness in transgenic mice expressing CTG expansions is associated with the activation of the ubiquitin–proteasome pathway |
|
| RBFOX1 cooperates with MBNL1 to control splicing in muscle, including events altered in myotonic dystrophy type 1 |
|
| rbFOX1/MBNL1 competition for CCUG RNA repeats binding contributes to myotonic dystrophy type 1/type 2 differences. |
|
| Replicative aging down-regulates the myogenic regulatory factors in human myoblasts. |
|
| Rôle de l'inclusion de l'exon 7 de BIN1 dans la faiblesse musculaire des patients atteints de dystrophie myotonique |
|
| Selective silencing of mutated mRNAs in DM1 by using modified hU7-snRNAs |
|
| Splicing misregulation of SCN5A contributes to cardiac-conduction delay and heart arrhythmia in myotonic dystrophy. |
|
| Steroid receptor RNA activator protein binds to and counteracts SRA RNA-mediated activation of MyoD and muscle differentiation |
|
| Stratégie thérapeutique par saut d'exon pour les épidermolyses bulleuses dystrophiques |
|
| Study of an alternative transcript of dysferlin and establishment of a treatment for dysferlinopathies. |
|
| Study of impairment selectivity in limb girdle muscular dystrophies using global approaches. |
|
| The study of the consequences of serca1's missplicing on muscle function in myotonic dystrophy type 1 |
|
| Targeting deregulated AMPK/mTORC1 pathways improves muscle function in myotonic dystrophy type I. |
|
| Therapeutic Approaches for Dominant Muscle Diseases: Highlight on Myotonic Dystrophy |
|
| Thérapie génique par saut d'exon : application à une Myopathie à Core et à un cas de syndrome OculoCérébroRénale de Lowe |
|
| Transplantation of Human Myoblasts in SCID Mice as a Potential Muscular Model for Myotonic Dystrophy |
|
| Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy. |
|
| Viral vector producing antisense RNA restores myotonic dystrophy myoblast functions |
|
